HK1223037A1 - 用於癌症靶向治療和診斷成像的包含基於修飾的血紅蛋白的治療劑的藥物組合物 - Google Patents

用於癌症靶向治療和診斷成像的包含基於修飾的血紅蛋白的治療劑的藥物組合物

Info

Publication number
HK1223037A1
HK1223037A1 HK16111399.6A HK16111399A HK1223037A1 HK 1223037 A1 HK1223037 A1 HK 1223037A1 HK 16111399 A HK16111399 A HK 16111399A HK 1223037 A1 HK1223037 A1 HK 1223037A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
therapeutic agent
diagnostic imaging
based therapeutic
cancer targeting
Prior art date
Application number
HK16111399.6A
Other languages
English (en)
Inventor
Bing Lou Wong
Norman Fung Man Wai
Sui Yi Kwok
Man Kin Wong
Comelia Wing Yin Man
Original Assignee
Vision Global Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vision Global Holdings Ltd filed Critical Vision Global Holdings Ltd
Publication of HK1223037A1 publication Critical patent/HK1223037A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41Porphyrin- or corrin-ring-containing peptides
    • A61K38/42Haemoglobins; Myoglobins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445Haemoglobin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043Fluorescein, used in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
HK16111399.6A 2013-05-13 2016-09-29 用於癌症靶向治療和診斷成像的包含基於修飾的血紅蛋白的治療劑的藥物組合物 HK1223037A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361822463P 2013-05-13 2013-05-13
PCT/US2014/037749 WO2014186301A1 (en) 2013-05-13 2014-05-13 Pharmaceutical composition comprising modified hemoglobin- based therapeutic agent for cancer targeting treatment and diagnostic imaging
US14/275,885 US9636404B2 (en) 2013-05-13 2014-05-13 Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging

Publications (1)

Publication Number Publication Date
HK1223037A1 true HK1223037A1 (zh) 2017-07-21

Family

ID=51864923

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16110826.1A HK1222574A1 (zh) 2013-05-13 2016-09-13 用於癌症靶向治療和診斷成像的包含基於修飾的血紅蛋白的治療劑的藥物組合物
HK16111399.6A HK1223037A1 (zh) 2013-05-13 2016-09-29 用於癌症靶向治療和診斷成像的包含基於修飾的血紅蛋白的治療劑的藥物組合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK16110826.1A HK1222574A1 (zh) 2013-05-13 2016-09-13 用於癌症靶向治療和診斷成像的包含基於修飾的血紅蛋白的治療劑的藥物組合物

Country Status (20)

Country Link
US (2) US9636404B2 (zh)
EP (1) EP3001813B1 (zh)
JP (1) JP6392855B2 (zh)
KR (1) KR102013015B1 (zh)
CN (1) CN105407911B (zh)
AU (1) AU2014265659B2 (zh)
BR (1) BR112015028340A2 (zh)
CA (1) CA2911414C (zh)
CL (1) CL2015003343A1 (zh)
EA (1) EA032164B1 (zh)
HK (2) HK1222574A1 (zh)
IL (1) IL242422B (zh)
MA (1) MA38571B1 (zh)
MX (1) MX362001B (zh)
MY (1) MY176175A (zh)
PH (1) PH12015502536A1 (zh)
SA (1) SA515370134B1 (zh)
SG (1) SG11201509042YA (zh)
TW (1) TWI610685B (zh)
WO (1) WO2014186301A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636404B2 (en) * 2013-05-13 2017-05-02 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
US9814759B2 (en) * 2014-07-02 2017-11-14 Cheer Global Ltd. Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
TW201609152A (zh) 2014-09-03 2016-03-16 免疫原公司 包含細胞結合劑及細胞毒性劑之偶聯物
TR201606102A2 (tr) * 2016-05-10 2016-10-21 Tolgay Tuyan Ilhan Karin i̇çi̇ uygulanan kanser tedavi̇leri̇nde oksi̇jen konsantrasyonu ölçümü yapabi̇len ve veri̇len oksi̇jen dozaji üzeri̇nde deği̇şi̇kli̇k yapmayi sağlayan ci̇haz
CA3028589A1 (en) * 2016-06-21 2017-12-28 Therapure Biopharma Inc. Hemoglobin-targeted drug delivery for the treatment of cancer
WO2018111989A1 (en) * 2016-12-14 2018-06-21 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
US11560384B2 (en) 2017-05-04 2023-01-24 University Of Utah Research Foundation Benzonorbornadiene derivatives and reactions thereof
CN107153771B (zh) * 2017-05-17 2020-06-30 许昌学院 一种药物分子的同步控制方法及其应用
US11504417B2 (en) 2017-07-18 2022-11-22 VirTech Bio, Inc. Blood substitutes comprising hemoglobin and methods of making
WO2021013131A1 (en) * 2019-07-19 2021-01-28 Cheer Global Limited Hemoglobin-based therapeutic agents
CN114605338B (zh) * 2022-05-11 2022-10-28 深圳厚存纳米药业有限公司 一种含尿嘧啶衍生物的纳米粒、核酸纳米复合物及其制备方法和用途
CN116068189A (zh) * 2023-04-07 2023-05-05 吉林重明生物科技有限公司 早期癌检测试剂及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584130A (en) * 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
MC2260A1 (fr) * 1990-06-18 1993-04-26 Dow Chemical Co Formulations de produits radiopharmaceutiques,leur methode d'administration et leur procede de preparation
ATE168014T1 (de) * 1991-11-08 1998-07-15 Somatogen Inc Hämoglobine als arzneimittelabgabesystem
EP0757694A4 (en) * 1994-04-29 1998-05-06 Univ Missouri THIOETHER COMPOUNDS FOR THE PREPARATION OF BIFUNCTIONAL CHELATING AGENTS FOR THERAPEUTIC RADIOPHARMACEUTICALS
US5998361A (en) * 1996-10-18 1999-12-07 University Of Maryland At Baltimore Polymerized hemoglobin
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US20050059576A1 (en) * 1998-04-30 2005-03-17 Adamson J. Gordon Targeted delivery of antiviral compounds through hemoglobin bioconjugates
EP1469011B1 (en) * 2003-04-17 2007-11-07 Ezio Panzeri Hemoglobin conjugates
US7235639B2 (en) 2003-04-23 2007-06-26 Ezio Panzeri Hemoglobin conjugates
WO2010059315A1 (en) * 2008-11-18 2010-05-27 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US8048856B1 (en) * 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US8084581B1 (en) * 2011-04-29 2011-12-27 Bing Lou Wong Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus
US20130052232A1 (en) * 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
US20140106004A1 (en) * 2012-10-12 2014-04-17 Bing Lou Wong Hemoglobin-based oxygen carrier-containing pharmaceutical composition for cancer targeting treatment and prevention of cancer recurrence
US9636404B2 (en) * 2013-05-13 2017-05-02 Vision Global Holdings Ltd. Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging

Also Published As

Publication number Publication date
CN105407911A (zh) 2016-03-16
EP3001813A4 (en) 2017-01-11
SA515370134B1 (ar) 2017-10-18
AU2014265659A1 (en) 2015-11-19
EA032164B1 (ru) 2019-04-30
MX362001B (es) 2019-01-03
CA2911414A1 (en) 2014-11-20
SG11201509042YA (en) 2015-12-30
EP3001813A1 (en) 2016-04-06
US10322180B2 (en) 2019-06-18
IL242422B (en) 2019-02-28
TWI610685B (zh) 2018-01-11
EA201501065A1 (ru) 2016-04-29
US20140335018A1 (en) 2014-11-13
MA38571B1 (fr) 2018-10-31
JP6392855B2 (ja) 2018-09-19
US9636404B2 (en) 2017-05-02
CL2015003343A1 (es) 2016-08-05
KR20160007536A (ko) 2016-01-20
PH12015502536B1 (en) 2016-02-22
US20170266285A1 (en) 2017-09-21
KR102013015B1 (ko) 2019-08-21
CA2911414C (en) 2018-09-11
WO2014186301A1 (en) 2014-11-20
EP3001813B1 (en) 2019-03-27
MY176175A (en) 2020-07-24
CN105407911B (zh) 2020-05-12
MA38571A1 (fr) 2017-10-31
WO2014186301A8 (en) 2015-02-05
AU2014265659B2 (en) 2017-03-30
MX2015015555A (es) 2016-05-09
TW201517921A (zh) 2015-05-16
HK1222574A1 (zh) 2017-07-07
PH12015502536A1 (en) 2016-02-22
JP2016518447A (ja) 2016-06-23
BR112015028340A2 (pt) 2017-09-19

Similar Documents

Publication Publication Date Title
HK1223037A1 (zh) 用於癌症靶向治療和診斷成像的包含基於修飾的血紅蛋白的治療劑的藥物組合物
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
PT3031826T (pt) Composição farmacêutica para o tratamento e/ou a prevenção do cancro
EP2818482A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
HUE046788T2 (hu) Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
EP2824114A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
HK1211979A1 (zh) 用於癌症靶向治療的含有結合白蛋白的精氨酸脫亞胺酶的藥物組合物
HK1223304A1 (zh) 包含二甲雙胍和二氫槲皮素的藥物組合及其用於治療癌症的用途
HK1232242A1 (zh) 用於癌症靶向治療的包含基於重組血紅蛋白蛋白質或亞基的治療劑的藥物組合物
HK1214526A1 (zh) 眼底疾病治療劑
EP2962693A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF CANCER
HK1209725A1 (zh) 苯達莫司汀衍生物和相關化合物,及其癌症治療的醫藥用途
EP2984170A4 (en) USE OF ANTIBODY UREASE CONJUGATES FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
PL2854748T3 (pl) Kompozycja farmaceutyczna do leczenia zapalenia skóry i powiązanych syndromów
IL246036A0 (en) A therapeutic and/or prophylactic substance containing a derivative of 1-indensulfamide for pain
EP3058960A4 (en) Diagnostic agent for therapeutic effect on cancer
EP2928540A4 (en) THERAPEUTIC CATHETER AND HIGH PRESSURE IMAGING
AP2015008848A0 (en) Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
EP2902027A4 (en) ACTIVE COMPOSITION FOR THE TREATMENT OF TUMORS AND THE USE THEREOF
EP2905284A4 (en) PHOTOSENSITIZATION TARGETING THYMIDINE KINASE AND PHARMACEUTICAL COMPOSITION AND USE FOR THE TREATMENT OF ASSOCIATED CANCER
GB201204287D0 (en) Therapeutic and diagnostic target
GB201204285D0 (en) Therapeutic and diagnostic target
GB201204206D0 (en) Therapeutic and diagnostic target
GB201204177D0 (en) Therapeutic and diagnostic target
GB201204166D0 (en) Therapeutic and diagnostic target